Open in interactive viewer → charts, metric popovers & call review

Carlsmed's Inflection Point Came With a DRG Code — and a New CFO

Q3 revenue rose 65% and guidance went up, but the 'inflection' is an adjusted construct built on $2.8M of one-timers and a finance bench rebuilt weeks before the print.
CARL · Earnings Call · 2026-11-10

An inflection point with a start date

For two quarters Carlsmed discussed the CMS inpatient payment rule the way you discuss weather three days out — real, directional, not yet actionable. Asked in May about the proposed IPPS rule, Michael Cordonnier declined to speculate: “It is early days, and it is a preliminary rule. We are really holding off on those discussions until the final rule goes into place.” — Michael Cordonnier, Chairman and Chief Executive Officer · 2026-05-05 The rule went into place on October 1, 2026, collapsing eleven lumbar MS-DRGs into three codes (523, 524, 525), and on this call the same executive had something he could actually measure: “We did see an uptick in new hospital acquisitions going on contract exiting Q3 and continuing through Q4.” — Michael Cordonnier · 2026-11-10 That is the news in this quarter, and it is why inflection point — a phrase absent from this company's keyword stack through the spring — now sits near the top of it beside DRG codes. The operating numbers behind the framing are genuinely strong: revenue of $21.6 million, up 65% from $13.1 million, procedure volume up 76%, and the trained surgeon user base up more than 60% year-over-year. Full-year guidance went from $74–78 million to $78–80 million, more than 56% growth at the midpoint. What makes this more than a beat-and-raise is that the reimbursement change is durable rather than a one-year add-on payment, and it arrives at the moment the company is pushing two new procedures through the same technology platform.

Two launches, one platform, one number that matters

The posterior bi-lateral lumbar system launched in mid-October and addresses roughly 30,000 procedures, about 7% of US lumbar fusions. The corra cervical plating system ships within weeks, and roughly 60% of ACDF procedures use fixation plates — meaning the cervical franchise stops being a stand-alone interbody story and becomes a full-procedure story. This is the lumbar procedure-to-cervical flywheel management has been promising since the December cervical launch, and it is now compounding faster than the model: “cervical mix as a percentage of the total in the third quarter was 12%.” — Richard Heppenstall · 2026-11-10 Recall what they told you in May: “high single-digit to low double-digit percent contribution of revenue from cervical in the total plan for the company looks about right.” — Michael Cordonnier, Chairman and Chief Executive Officer · 2026-05-05 Twelve percent in Q3, with another ~3 points of mix gain over the last few quarters, is a guidance miss in the good direction — the first time this management team has materially beaten its own mix assumption. The commercial launch cadence is the tell: this is a company adding procedures to a shared digital production and planning stack rather than building new factories. Gross margin of 77.3% (up ~140bps) on a capital-light model is the proof: gross margin has climbed from 75% at the 2024 launch to 77.3%, with the two-year move worth roughly +2 points.

The bill for the inflection

Here the story gets less tidy. G&A came in at $10 million against $4.9 million, and $2.3 million of that is executive transition costs plus the resolution of certain legal matters — two phrases that did not exist in this company's earnings vocabulary until this quarter and now rank as top-25 keywords in it. A further $0.5 million of transition cost landed, oddly, inside R&D. Add the personnel news — Rich Heppenstall arriving as CFO from ZimVie, Jeff Bertolini promoted to COO, and an ex-Intuitive Surgical AI chief installed in a newly created product role on October 1 — and you have three senior seats changed within about six weeks of the print. That is not scandal; it is a company declaring it is entering a different operating phase. But it means the quarter's headline profitability claim needs the footnote.

Q3 was the first quarter where our sales growth and strong gross margins generated positive operating leverage on our profitability.

Richard Heppenstall · 2026-11-10
True on an adjusted basis: adjusted EBITDA improved to −$7.3 million from −$8.2 million. On GAAP, operating income was still −$11 million in the last reported period with a −58% operating margin, and the loss has widened as revenue has grown. The bridge is stock compensation: the SBC add-back is running up more than 7x year-over-year, and Q4 guidance of $2.75–3 million implies SBC alone near 14% of guided quarterly revenue. SG&A, meanwhile, is up 128% year-over-year versus revenue's 57%. Operating leverage, in other words, arrives only after you exclude roughly $2.8 million of items the company chose to exclude. Cash is not the issue: $80.3 million against $9 million of quarterly burn buys time, and the $15.6 million drawn on a $50 million facility maturing in 2030 is genuinely cheap, non-dilutive runway.

What the tape already knew

The stock had already voted. Carlsmed rose 56.7% in the ninety trading days into this report, sitting about 8.6% below an August 28 high of $16.88 — a sharp re-rating for a $402 million market cap that works out to roughly five times the new guide's midpoint. When a name runs that far into a print, the print's job is to confirm rather than reveal, and the revenue beat and raise did that. One nuance in the language: reimbursement was this company's single strongest rising theme in the prior quarter, when the DRG change was still a proposal. Now that it is live, the word has migrated from aspiration to fact, and management talks about hospital contracting mechanics rather than advocacy. That is a healthy transition — and it lines up with a broader market appetite for procedure-migration economics, the same site of service trade that has bid up orthopedic and payer names over the past year. Conversely, spine surgery faded as a keyed theme even as revenue accelerated: the company is deliberately repositioning from a spine-procedure vendor to a personalized-surgery platform, and aprevo cervical is the vehicle for that rewrite. The thing to watch is the guidance habit. Pressed twice on why Q4's implied sequential step-up is modest despite the DRG tailwind and two launches, Cordonnier gave the same answer he has given since the IPO: “as a newly public high-growth med tech company, we continue to be prudent with our guidance.” — Michael Cordonnier · 2026-11-10 He said a version of this in February — “as a newly public company, we want to make sure that we're prudent with our guidance” — Michael Cordonnier, Chief Executive Officer and Chairman · 2026-02-25 — and then beat. Four quarters of sandbagging is a credibility asset, not a red flag, but it does mean the 2027 setup is doing more work in the stock than the 2026 guide is.